Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6192707 | Journal of Thoracic Oncology | 2016 | 16 Pages |
Abstract
We report an anaplastic lymphoma receptor tyrosine kinase gene (ALK)-positive patient who showed a paradoxical response to the ALK inhibitor alectinib; the primary lesion increased in size, whereas other metastatic lesions decreased markedly. A biopsy of the primary lesion confirmed an ALK rearrangement; however, the tumor had transformed histologically into small cell lung cancer. The lack of reports of small cell lung cancer transformation in ALK-positive patients implies that this outcome was unusual; this patient was treated with alectinib, which is more selective and has a greater inhibitory effect than crizotinib. This case may reveal resistance mechanisms that differ according to the agent used for treatment.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Shiro MD, PhD, Katsuhiro MD, PhD, Nobuyuki MD, PhD, Yasushi MD, PhD,